Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Decision to treat with Interferon Beta-1a (IFN beta-1a) must precede enrollment, independently of the study and in compliance with the marketing authorization
Study enrollment must occur prior to 4th weekly administration of IFN beta-1a
Able to understand and complete a self-administered questionnaire
No contra-indications for IFN beta-1a
You may not be if
Subjects with history of hypersensitivity to natural or recombinant IFN beta or to any component
Subjects with primary or secondary progressive MS
Subjects with current severe depression and/or suicidal ideation
Pregnant women
Subjects participating in another clinical trial
Subjects who do not want to participate in the study
Clareo Health | Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study
